Kalaris Therapeutics Stock (NASDAQ:KLRS)
Previous Close
$1.99
52W Range
$1.87 - $11.88
50D Avg
$3.16
200D Avg
$5.58
Market Cap
$40.84M
Avg Vol (3M)
$72.16K
Beta
0.21
Div Yield
-
KLRS Company Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.